Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma

Trial Profile

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs CMD 501 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Neuroblastoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 26 Sep 2018 New trial record
    • 20 Sep 2018 According to a Cell Medica media release,this trial is part of Cell Medicas collaboration with Baylor College of Medicine and Texas Childrens Hospital.This study is supported by a grant from Alexs Lemonade Stand Foundation (ALSF), awarded to BCM investigators, Drs. Heczey and Metelitsa.
    • 20 Sep 2018 According to a Cell Medica media release, the first neuroblastoma patient has been successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT) in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top